HEMOPHILIA A AND B
-
The World Federation of Hemophilia/European Haemophilia Consortium statement on very rare adverse events with COVID-19 vaccines
April 12, 2021 — Please see the World Federation of Hemophilia/European Haemophilia Consortium statement on very rare adverse events with COVID-19 vaccines: www1.wfh.org/docs/website/en/News/WFH-EHC-Statement-on-EMA-April2021.pdf The key...
-
Medical, nursing and patient groups unite to contest INESSS report on Hemlibra
Montreal, March 29, 2021 – Medical and patient groups in Quebec and across Canada have united in their rejection of the recommendation by Quebec’s health...
-
CHS replies to Quebec’s INESSS following its shocking report on the funding of Hemlibra
The Institut national d’excellence en santé et en services sociaux (INESSS) released its recommendation on funding Hemlibra (emicizumab) for the treatment of severe hemophilia A...
-
Fitusiran trial restarts with new controls
BRUSSELS – During the European Association for Haemophilia and Allied Disorders (EAHAD) virtual congress session on the latest clinical trial, Dr. Shauna Anderson, representing Sanofi,...
-
Community awaits decisions on access to Hemlibra
Montreal, February 4, 2021 – The hemophilia community is awaiting decisions by Canadian health authorities on access to Hemlibra for people with hemophilia A without...